CLASS II Device recall · Reported 2 May 2018 · FDA Enforcement Report

Oncomine Dx Target Test recalled by Life Technologies

Life Technologies is recalling Oncomine Dx Target Test, (, distributed in Arizona, California, North Carolina, Texas, Virginia. The recall was initiated on 8 Feb 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot 1705001 UDI: (01)10190302006385(17)180220(10)1705001(240)A32441
Quantity recalled30

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1480-2018
FDA event ID
79649
Recalling firm
Life Technologies, Frederick, MD
Classification
Class II
Status
Terminated
Recall initiated
8 Feb 2018
FDA classified
20 Apr 2018
Reported
2 May 2018
Type
Voluntary: Firm initiated
Customers notified by
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Reason category
Other Reasons

Timeline

8 Feb 2018Recall initiated by company
20 Apr 2018Classified by FDA+71 days
2 May 2018Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The lower concentration of the RNA panel could cause a NO CALL or FALSE NEGATIVE for the reporting of ROS1 fusion. If a physician relies on a false negative result, crizotinib could be improperly excluded from the patient's treatment regimen.

Product as listed by the FDA

Oncomine Dx Target Test, (Model No. A32451), Oncomine Dx Target RNA/DNA Panel (Model No. A32441). A qualitative In Vitro Diagnostic test.

Where it was distributed

Distributed to states: AZ, CA, NC, TX, and VA.

ArizonaCaliforniaNorth CarolinaTexasVirginia

Stores named: Target

Questions about this recall

Is Oncomine Dx Target Test, ( recalled?

Yes. Life Technologies recalled Oncomine Dx Target Test, ( on 8 Feb 2018. The recall is Class II and its status is Terminated. Recall number Z-1480-2018.

Why was it recalled?

The lower concentration of the RNA panel could cause a NO CALL or FALSE NEGATIVE for the reporting of ROS1 fusion. If a physician relies on a false negative result, crizotinib could be improperly excluded from the patient's treatment regimen.

Which lots are affected?

Lot 1705001 UDI: (01)10190302006385(17)180220(10)1705001(240)A32441

Where was it sold?

Distributed to states: AZ, CA, NC, TX, and VA.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Life Technologies

All 23

Other Test Kits & Diagnostics recalls

All 2,656